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Abstract
Background: Interleukin 18 (IL-18) promoter polymorphisms (¡656G > T, ¡607C > A, and ¡137G > C) affect serum IL18 (sIL-18) levels and are associated with renal injury.
Purpose: This study aimed to determine the diagnostic utility of sIL-18 and urine IL-18 (uIL-18) as biomarkers for acute
kidney injury (AKI) and analyse the association of IL-18 polymorphisms to AKI in preterm infants.
Methods: Blood and urine samples were collected from 56 preterm infants with AKI and 56 without AKI to measure
serum creatinine (SCr), sIL-18, and uIL-18. Genotyping of polymorphisms was performed and analysed, with AUCROCs analysis used to evaluate the diagnostic utility of s-/uIL-18 levels.
Results: The median sIL-18 and uIL-18 levels were signiﬁcantly higher than those without AKI. For a cutoff of >132 pg/
mL, the sIL-18 expression had sensitivity and speciﬁcity of 80.36% and 60.71%, respectively, while for uIL-18, a cutoff of
>900.7 pg/mL had sensitivity and speciﬁcity of 51.79% and 78.57%, respectively. The odds ratio of sIL-18 and uIL-18 to
predict AKI in preterm infants was 5.89 (95%CI:2.31e15.02) and 4.15 (95%CI:1.58e10.89), respectively. The polymorphisms ¡137G > C and ¡656G > T were signiﬁcantly associated with sIL-18 expression.
Conclusion: Serum and urine IL-18 levels are risk factors for and a moderate predictor of AKI in preterm infants.
Keywords: Acute renal injury, Polymorphism, Premature, Serum IL-18, Urine IL-18

1. Introduction

A

ccording to CDC data in 2019, the incidence
of preterm birth is 10e15%, with a high rate
of morbidity, especially at a gestational age of less
than 33e34 weeks due to the immaturity of the organs [1e6]. Several studies have shown that acute
kidney injury (AKI) in preterm neonates has shortterm and long-term effects on the kidney [1e9].
However, there is no consensus on the best practice
for the diagnosis of neonatal AKI, partially due to
neonatal serum creatinine (SCr) levels in the ﬁrst
48e72 h of life being inﬂuenced by the maternal
creatinine level [8e12]. The latest diagnostic criteria

for AKI as proposed by the Acute Kidney Injury
Working Group of KDIGO (Kidney Disease:
Improving Global Outcomes) is based in absolute
increase of sCr, at least 0.3 mg/dL (26.5 mmol/L)
within 48 h or by a 50% increase in sCr from baseline within 7 days, or a urine volume of less than
0.5 mL/kg/h for at least 6 h [12, 13].
Preterm birth is associated with maternal inﬂammation during pregnancy, marked by an imbalance
of interleukins (IL), particularly, IL-6, IL-10, IL-18
and tumour necrosis factor-alpha (TNFa) [14e16]. It
has been reported that IL-18 is associated with AKI,
with adults having an increase in IL-18 after 24 h of
renal ischemia or decreased perfusion, especially in
the proximal tubule [14e17]. A previous study in
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neonatal term infant showed that urine IL-18 (uIL18) can be used as a predictor of AKI with sensitivity
more than 90% [18], another study in neonatal critically ill had a sensitivity of 64% and a speciﬁcity of
92% [19]. Furthermore, IL promoter polymorphisms
are known to affect cytokine expression levels. Five
single nucleotide polymorphisms (SNPs) in the
promoter area and exon 1 of IL-18 gene have been
identiﬁed, i.e. 137 G > C, 607C > A, 656 G > T,
þ113 T > G and þ127C > T, with 137 G > C
(rs187238), 607C > A (rs1946518), and 656 G > T
(rs1946519) affecting IL-18 expression [20e28].

2. Purposes
This study aims to determine the utility of sIL-18 and
urine interleukin 18 (uIL-18) as biomarkers of AKI in
preterm infants and whether the 137 G > C (rs187238),
607C > A (rs1946518) and 656 G > T (rs1946519)
polymorphisms are associated with the expression levels
of s-/uIL-18 and AKI phenotype in preterm infants.

3. Methods
3.1. Study design and subjects
This caseecontrol study recruited 112 neonates
born at 30e36 weeks of gestation, with written
informed consent from parents obtained prior to
inclusion. Sample size was determined based on
formula for comparing two proportion with signiﬁcance level 5% (one tailed); power of test 80%; and
P1 ¼ proportion of genotype IL-18 allele C ¼ 0.19
[20] (P1 is the highest Minor Allele Frequency
among three polymorphism of IL-18 promoter
polymorphism), with OR ¼ 3; and for formula P1 ¼
P2 *OR/((1þP2 (OR-1)) ¼ 0,57/(1.38) ¼ 0.42. From the
formula sample size derived at least n ¼ 47 for each
group. By setting a drop out ¼ 10%, the minimum
sample size will be: 1/(1-0,10) * 47 ¼ 53 per group.
The study protocol was approved by the Faculty of
Medicine, University of Padjadjaran Bandung (Ethical
clearance number 72/UN6.KEP/EC/2019). The subjects were divided into two groups: the case group (56
infants with AKI) and the control group (56 infants
without AKI) and the diagnosis of AKI was according
to the neonatal-KDIGO (nKDIGO) criteria, that is, an
increase in serum creatinine of 0.3 mg/dL in the last
48 h or a 150e200% increase in serum creatinine level
compared to baseline, and a urine volume of less than
0.5 cc/kg/h. Samples were collected consecutively. The
exclusion criteria were oligohydramnion, maternal
infection, and multiple congenital abnormalities.
Trained health personnel were collected blood
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samples (1 mL) from the umbilical vein and urine
samples were obtained via a urinary catheter. All
biological samples were directly transported to the
clinical laboratory of Dr Hasan Sadikin Hospital for
biochemical analysis and the molecular genetics laboratory for DNA isolation within 2 h after collection.
3.2. Measurement of serum creatinine and urine/
serum IL-18
Serum creatinine was measured within the ﬁrst
24 h and repeated on day 3 (72e96 h post-natal)
using a modiﬁed kinetic technique CRE2 method
(Dimension Vista System Creatinine/Siemens
Healthcare Diagnostic)R. IL-18 levels were
measured in the serum and urine of the subjects in
the ﬁrst 24 h using an ELISA.
3.3. Genotyping of IL-18 promoter polymorphisms
DNA was isolated from 300 to 500 ml of blood
using a Quick-DNA Miniprep Plus kit (Zymo
Research, CA, USA). Polymerase chain reaction
(PCR) was performed using 50e100 ng of DNA, 25 ml
of MyTaq™ HS Red Mix (Bioline), 1 ml of 10 pmol/ml
of each forward and reverse primers and MQ water
(Millipore; to total volume of 50 ml). Primers used to
amplify each SNPs in this experiment are presented
in Table S1 and the PCR was performed on a touchdown PCR machine with an annealing temperature
ranging from 65οC to 55οC for a total of 35 cycles
(Table S2). The PCR products were subjected to gel
electrophoresis (1.5% agarose gel) and puriﬁed for
Sanger sequencing on an ABI-3500. The sequencing
results were analysed using Bioedit Software.
3.4. Statistical analysis
Descriptive analyses were performed with data
expressed as frequency and percentage for categorical data. Statistical analysis was performed
using an independent t-test or the ManneWhitney
U test. Univariate statistical analysis continued
with bivariate logistic regression was conducted to
analyse prominent risk factors that relate simultaneously to the outcome. Area under the receiveroperating characteristic curve (ROC-AUC) analysis,
positive predictive value (PPV) and negative predictive value (NPV) were used to evaluate the
diagnostic utility of the serum and urine IL-18 level.
The risk was analysed using the odds ratio (OR)
with a 95% conﬁdence interval and a two-tailed
p < 0.05 was considered signiﬁcant.
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4. Results
4.1. Subject characteristics
There were no signiﬁcant differences in gender,
gestational age and birth weight in preterm infants
with and without AKI. The level of serum IL-18 and
urine were signiﬁcantly higher in preterm infants
with AKI than non-AKI infants (p < 0.05) (Table 1).
4.2. Expression of sIL-18 and uIL-18 in preterm
infants
Based on the differences in sIL-18 and uIL-18
levels in preterm infants with and without AKI, a cut
off point of IL-18 to predict AKI was determined by
AUC-ROC analysis (see Figs. 1, 2). The results
showed that the AUC-ROC for the utility of sIL-18
for AKI in preterm infants was 0.72 (95%CI:
0.494e0.863). The cut off point was >132 pg/mL,
with a sensitivity of 80.36% and speciﬁcity of 60.71%.
This test had a PPV of 58.44% and NPV of 75.56%.
For uIL-18 levels, the AUC-ROC was 0.62 (95%CI:
0.532e0.718) with a cut off point of >900.7 pg/mL
having a sensitivity of 51.79% and speciﬁcity of
78.57%. This test had a PPV of 70.73% and NPV of
61.97% (Table .2).
Signiﬁcant factors from the above calculations, cut
off points of serum IL-18 (>132 pg/mL) and urine IL18 (>900.7 pg/mL) were included in the multiple
logistic regression to assess the relationship of these
factors to the incidence of AKI in preterm infants,
Table 1. Characteristics of preterm infants with AKI and without AKI.
Characteristics

(þ) (n ¼ 56)
Gender
Boy
27 (48.2)
Girl
29 (51.8)
Gestational ages (weeks)
Mean (SD)
32.3 (1.4)
Median
32
Range
30e36
Birth weight (gr)
Mean (SD)
1665.8 (309.4)
Median
1630
Range
1000e2210
Serum IL-18 (pg/mL)
Mean (SD)
266,8 (366,5)
Median
167,4
Range
30,7e2118,9
Urine IL-18 (pg/mL)
Mean (SD)
1181,0 (1278,0)
Median
918,7
Range
156,5e7003,3
a

pa

AKI

Fig. 1. ROC curve for the utility of serum IL-18 for the prediction of AKI
in preterm infants. AUC ¼ 0.72 (95%CI: 0.494e0.863) with a cut-off
point >132 pg/mL: sensitivity 80.36%; speciﬁcity 60.71%.

IL8 urine (pg/mL)
100
80
60

() (n ¼ 56)
0.85

40

0.82

20

26 (44.8)
27 (47.4)
32.3 (1.4)
32
30e36
0.970
1639 (324.7)
1645
1100e2320
<0.001
130,3 (268,9)
117,8
26,5e877,6
0.010
726,9 (600,1)
649,8
96,8e3266,2

Gestational age and serum/urine IL-18 Level by
ManneWhitney test; birth weight with t-test; gender using the
Chi-square test.

AUC = 0.641
P = 0.007

0
0

20

40

60

80

100

100-Specificity
Fig. 2. ROC curve of urine IL-18 used as a predictor of AKI in preterm
infants. AUC ¼ 0.62 (95%CI: 0.532e0.718) with a cut-off point
>900.7 pg/mL: sensitivity 51.79%; speciﬁcity 78.57%.

showing that the ORadj of sIL-18 was 5.89 (95%
CI:2.31e15.02), 4.15 (95%CI:1.58e10.89) for uIL-18
(Table 3).
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Table 2. Diagnostic analysis of serum and urine IL-18 levels as predictor of AKI in preterm infant.
Cut off point

AKI

IL-18 serum:
>132 pg/mL
132 pg/mL
IL-18 urine:
- >900.7 pg/mL
-  900.7 pg/mL
a

þ

e

45
11

22
34

29
27

12
44

pa

Note

<0.001

Sensitivity 80.36%; Speciﬁcity 60.71%; PPV ¼ 58.44%; and NPV ¼ 75.56%

0.001

Sensitivity 51.79%; Speciﬁcity 78.57%; PPV ¼ 70.73%; and NPV ¼ 61.97%

Based on Chi square test.

Table 3. The factors associated with the incidence of AKI based on multiple logistic regression analysis.
Variable

Coefﬁcient B

SE (B)

P-value

ORadj (CI 95%)

IL-18 serum (>132 pg/mL)
IL-18 urine (>900,7 pg/mL)

1.774
1.423

0.477
0.492

<0.001
0.004

5.89 (2.31e15.02)
4.15 (1.58e10.89)

Accuracy ¼ 85%; R2 (Nagelkerke) ¼ 39%; ORadj (CI 95%): Odds ratio adjusted and Conﬁdence interval 95%.

4.3. Association of IL-18 promoter polymorphisms
with s/uIL-18 levels

infants with homozygous mutant (T/T) than the
homozygous wild type (G/G) (198.4 vs 178.8 pg/mL;
Table 4).

The results of the association analysis of
137G > C, 607C > A and 656G > T polymorphisms with sIL-18 and uIL-18 levels in preterm
infants showed that only 137G > C and 656G > T
polymorphisms signiﬁcantly affected the level of
sIL-18 in preterm infants with AKI (Table 4).
Post-hoc analysis of 137G > C and 656G > T
showed that the change of homozygote wild type
(G/G) to heterozygote (G/C) of 137G > C polymorphism signiﬁcantly affected the sIL-18 level
(Table 5), with the median sIL-18 level higher in
infants with the mutant heterozygous (G/C) than
those homozygous wild type (G/G) (166.8 vs
138.4 pg/mL; Table 4). Also, the change of homozygote wild type (G/G) to homozygote mutant (T/T)
of 656G > T (rs1946519) signiﬁcantly affected the
sIL-18 level, with a median sIL-18 level higher in

4.4. Association of genotype and allele of IL-18
promoter polymorphisms with AKI in preterm
babies
The association analysis of the genotype
137G > C, 607A > C and 656G > T polymorphisms with preterm AKI presented in Table 6
showing that none of the IL-18 promoter polymorphism genotypes was associated with AKI in
preterm infants (p > 0.05, OR<1.00). Likewise, there
was no association of any of the mutant alleles of the
IL-8 promoter polymorphisms with AKI in preterm
infants (Table 7). Although it was not signiﬁcant,
there was a trend that the mutant allele slightly
increased the risk of AKI in preterm babies as all of
the OR values were >1.00 (Table 6).

Table 4. Association of IL-18 promoter genotype polymorphisms with sIL-18 and uIL-18.
Polymorphisms
137G > C(rs187238)
GG
GC
CC
607C > A(rs1946518)
CC
CA
AA
656G > T(rs1946519)
GG
GT
TT
a

N

%

IL-18 Serum (pg/ml)
Median

Range

p

IL-18 Urine (pg/ml)
Median

Range

783.5
689.7
978.3

113.8 -7,003.3
96.8e7,003.2
241.1e1,292.9

796.3
702
711.7

113.8e3,266.2
96.8e7,003.2
241.1e7,003.3

666
702
666

113.8e3,266.2
96.8e7,003.2
241.1e7,003.3

0.02
77
33
2

67.8
29.6
2.6

138.4
166.8
183.4

26.5e2,118
58.8e781.8
173.6e193.3

47
48
17

41.74
42.61
15.65

141
139.2
166.2

33.2e2,118.9
26.5e781.8
58.8e877.6

47
46
19

41.74
40.87
17.39

198.4
141.7
178.8

33.2e2,012.7
26.5e781.8
58.8e2,118.9

0.79

0.09

0.70

0.05

KruskaleWallis test.

pa

0.52
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Table 5. Post-hoc analysis of polymorphism genotype association with
serum IL-18.
Pa

Polymorphisms
137G > C (rs187238)
G/G vs G/C
G/G vs C/C
G > C vs C/C
656G > T (rs1946519)
G/G vs G/T
G/G vs T/T
G/T vs T/T
a

0.01
0.22
0.89
0.26
0.02
0.12

ManneWhitney test.

Table 6. Association of IL-18 polymorphism genotype with AKI among
preterm neonates.
Polymorphisms

Preterm Neonates
AKI (þ)

AKI ()

(n ¼ 56)

(n ¼ 56)

¡137G > C (rs187238)
G/G
35
G/C
20
C/C
1
¡607C > A (rs 946518)
C/C
21
C/A
24
A/A
11
¡656G > T(rs1946519)
G/G
21
T/G
23
T/T
12
a

Pa

OR (CI 95%)

0.35
42
13
1

0.833 (0.05e13.81)
0.538 (0.08e26.82)
1.0
0.37

26
24
6

0.44 (0.14e1.39)
0.55 (0.17e1.71)
1.0
0.47

26
23
7

0.47 (0.16e1.41)
0.58 (0.19e1.75)
1.0

ChieSquare test.

5. Discussion
Inﬂammation is the most common cause of preterm birth [14e16]. It has been established that IL-18
is involved in the pathogenesis of inﬂammation,
tumours, hemophagocytic syndrome, sepsis, AKI,
various autoimmune diseases and cardiac ischemia
[28e34]. Serum creatinine is not an ideal biomarker
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for AKI in preterm infants as it is inﬂuenced by
maternal creatinine level in the ﬁrst 48e72 h of life
[1e10]. Hence, this study sought to determine the
modality of sIL18 and uIL-18 as early biomarkers for
AKI in preterm infants and analyse the association
of the IL-18 promoter polymorphisms with s-/uIL18 and the risk of AKI in preterm infants.
In this study, the gestational age and birth weight
did not affect the incidence of AKI in preterm infants, which was different from the study of Shalaby
et al. (2018) [35] in Saudi Arabia, who showed that
gestational age and birth weight affected the incidence of AKI in newborns. This difference may be
attributed to our homogenous sample, with the
same criteria for subjects with and without preterm
AKI, whereas Shalaby et al. included newborns
from term until a gestational age of less than 30
weeks [35]. Nonetheless, the level of sIL-18 and uIL18 in preterm infants with AKI was signiﬁcantly
higher than that without AKI. Furthermore, multiple logistic regression analysis showed that the cut
off of sIL-18 > 132 pg/mL and uIL-18 > 900.7 pg/mL
increased the risk of AKI to 5.89 and 4.15 fold,
respectively, in preterm infants with AKI compared
to those without AKI. The AUC-ROC analysis
showed that sIL-18 and uIL-18 could be used as
moderate biomarkers to predict AKI in preterm infants, in line with Parikh et al.(2006) [36] and Wang
et al. (2017) [37], who reported that IL-18 level can be
used as an early biomarker and prognosis for AKI
[31,32]. Others study reported similar result with
this study, that IL-18 could be used as biomarker for
AKI [38e40].
The association analysis of polymorphisms with
IL-18 expression showed that infants with
137G > C and 656G > T polymorphisms had
signiﬁcantly higher sIL-18 compared to those with
the homozygous wild type. These results show that
there is an overlap in the polymorphisms which

Table 7. Association of IL-18 polymorphism alleles with preterm AKI.
Polymorphism alleles

¡137G > C (rs187238)
Allele C
Allele G
¡607C > A (rs 946518)
Allele A
Allele C
¡656G > T (rs1946519)
Allele T
Allele G
a

ChieSquare test.

AKI
(þ)

()

(n allele ¼ 98) N(%)

(n allele ¼ 132) N(%)

22 (20)
90 (80)

15 (15.2)
97 (84.8)

46 (42.8)
66 (57.2)

36 (32.1)
76 (67.9)

47(41.8)
65 (58.2)

37 (33.0)
75 (67.0)

Pa

OR (CI 95%)

0.208

1.43 (1.02e2.85)

0.165

1.55 (1.09e2.67)

0.168

1.34 (1.18e2.30)
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affect IL-18 expression in AKI preterm infants with
those in adult patients with kidney transplantation
(137G > C and 607C > A) and with type 1 diabetes, rheumatoid arthritis and Chron's disease
(656G > T, 607C > A and 137G > C) [20e28]. A
common feature of these phenotypes is the symptoms of chronic inﬂammation, indicating that these
polymorphisms increase the expression of sIL-18
which leads to chronic inﬂammation, hence is
involved in disease development. In this study, both
the change from homozygote (G/G) genotype to
heterozygote (G/C) of the 137G > C polymorphism
and the change of homozygote wild type (G/G) to
homozygote mutant (T/T) but not the heterozygous
(G/T) of the 656G > T (rs1946519) polymorphism
signiﬁcantly increased sIL-18 expression. However,
it is of note that only two infants had the homozygous mutant (C/C) of 137G > C, whereas nineteen
infants had the homozygous mutant (T/T) of
656G > T. Nonetheless, the trend of increasing sIL18 expression from homozygous wild type, heterozygous to homozygous mutants was evident in all
polymorphisms, indicating that there is a “dosageeffect of mutant allele”, in which the effect of homozygous mutant to increase the sIL-18 expression
is higher than that of heterozygous mutant. Further
studies employing a larger sample size are required
to conﬁrm this observation.
This study shows that both the genotype and alleles
of 137G > C, 607A > C, and 656G > T polymorphisms were not associated with the incidence of
AKI in preterm infants. Nonetheless, the analysis of
the association of the mutant alleles of the three
polymorphisms with the incidence of AKI in preterm
infants demonstrated a tendency for mutant alleles to
increase the risk of developing AKI as all OR values
were above 1.00 (1.34e1.55). It can be assumed that the
genetic effect of those polymorphisms on the risk of
AKI in preterm infants is weak, hence, the association
analysis of 112 samples of both cases and controls is not
sufﬁciently powered to detect a genetic association.
In this study, it has been shown that the IL-18 gene
promoter polymorphism is associated with sIL-18,
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however, AKI is a multifactorial disease inﬂuenced by
the interactions between multiple susceptibility genes,
numerous pro-inﬂammatory cytokines and environmental factors [37e41]. Most likely, there will not be a
single gene or environmental factor that has a large
effect on AKI susceptibility. Other risk factors, such as
inﬂammation with increased levels of CRP and
immaturity of the kidney itself in preterm infants have
a signiﬁcant role in the occurrence of AKI [42]. Thus, it
is not surprising that the effect of IL-18 gene promoter
polymorphisms on the occurrence of AKI is small as its
effect on the aetiology of the disease is indirect by
regulating the expression of IL-18.

6. Conclusion
This study demonstrated that increasing sIL-18
and uIL-18 are risk factors, as well as moderate
biomarkers for AKI in preterm infants. The
137G > C and 656G > T polymorphisms affect
sIL-18 but not uIL-18, however, none of those
polymorphisms are a risk factor for AKI in preterm
infants in this population. Larger-scale studies
should be conducted to conﬁrm the relationship
between IL-18 polymorphisms and the risk of AKI
in preterm newborns in Indonesia.
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Supplementary.

Table S1. Primers for genotyping IL-18 polymorphisms.
No

SNP Target

Primer sequence 5’ / 30

PCR product size (bp)

TM (οC)

1

137G > C (rs187238)

562

2
3

607A > C (rs946518)
656G > T (rs1946519)

Fw: TGACACCATATTGAGCTTGG
Rv: CAATTCCTTGCTGACTGTCC
Fw: TTTACACTCTGCTCTTCAAACG
Rv: CTTCCTGGTCACACTTCAGC

57.12
58.29
57.39
58.44

Fw: Forward, Rv: Reverse.

572
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Table S2. Touch-down PCR programme used for genotyping IL-18 polymorphisms.
No.

Temperature (οC)

Time (minutes)

1

94

5

2
3
4

94
68 reduce 1οC/cycle
72

1
1
1

10 cycles

5
6
7
8

94
58
72
72

1
1
1
5

25 cycle

9

4

~
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